SAN CARLOS, Calif. (AP) — SAN CARLOS, Calif. (AP) — Iovance Biotherapeutics Inc. (IOVA) on Thursday reported a loss of $78.6 million in its fourth quarter. On a per-share basis, the San Carlos ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On Friday, Piper Sandler analyst Joseph Catanzaro adjusted the price target for Iovance Biotherapeutics (NASDAQ:IOVA) to $6.00, down from the previous $7.50. The ...

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic ...

SAN CARLOS, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, ...

The market expects Iovance Biotherapeutics (IOVA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known ...